Acadia Pharmaceuticals
ACAD
264 hedge funds and large institutions have $2.62B invested in Acadia Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 109 increasing their positions, 79 reducing their positions, and 39 closing their positions.
120% more call options, than puts
Call options by funds: $13.5M | Put options by funds: $6.12M
38% more repeat investments, than reductions
Existing positions increased: 109 | Existing positions reduced: 79
3% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 39
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
0.54% less ownership
Funds ownership: 98.06% → 97.52% (-0.54%)
1% less funds holding
Funds holding: 267 → 264 (-3)
12% less capital invested
Capital invested by funds: $2.99B → $2.62B (-$369M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$47.3M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$36.3M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$21.9M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$15.8M |
| 5 |
Morgan Stanley
New York
|
+$15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$75M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$49.7M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$26.3M |
| 4 |
Prudential Financial
Newark,
New Jersey
|
-$16.7M |
| 5 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$13.6M |
ACAD Hedge Fund Activity: Q2 2024 in Review
264 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q2 2024, worth a combined $2.62B — down 12% from $2.99B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new ACAD positions and 39 closed out — a net gain of 1 holder — while 109 added to existing stakes and 79 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $47.3M. The largest seller was EcoR1 Capital, cutting an estimated $75M.
- 264 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q2 2024, down from 267 in Q1 2024.
- Funds reported $2.62B of Acadia Pharmaceuticals stock for Q2 2024, down 12% quarter-over-quarter.
- 40 funds opened new Acadia Pharmaceuticals positions in Q2 2024 and 39 closed out, a net change of +1 holder.
- The largest Acadia Pharmaceuticals buyer in Q2 2024 was Point72 Asset Management, an estimated $47.3M added.
- The largest Acadia Pharmaceuticals seller in Q2 2024 was EcoR1 Capital, an estimated $75M sold.
Based on aggregated 13F filings for Q2 2024.